(Q38526452)

3 September 2017

1 reference

title

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma (English)

1 reference

3 September 2017

1 reference

2

Pieter Sonneveld

1 reference

3 September 2017

1

Antonio Palumbo

1 reference

3 September 2017

publication date

12 June 2015

1 reference

Expert Review of Hematology

3 September 2017

published in

1 reference

3 September 2017

volume

8

1 reference

3 September 2017

issue

4

1 reference

3 September 2017

page(s)

481-491

1 reference

Multiple myeloma - current issues and controversies

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Melphalan and its role in the management of patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

European perspective on multiple myeloma treatment strategies: update following recent congresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Pomalidomide for patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Management of older adults with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Immunodeficiency and immunotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Fact or fiction--identifying the elusive multiple myeloma stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Immunologic microenvironment and personalized treatment in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Have drug combinations supplanted stem cell transplantation in myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

21 January 2018

Novel immunotherapies

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

SLAM-family receptors: immune regulators with or without SAP-family adaptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

The role of natural killer cells in immunity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Multiple myeloma : recent progress in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Novel lenalidomide-based combinations for treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1053866

10.1586/17474086.2015.1053866

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference